Original Article
Effect of Ciprofloxacin and Levofloxacin on the QT Interval: Is This a Significant "Clinical" Event?
Abstract
Background:The widespread use of the fluoroquinolones has raised the question of the cardiac safety of these medications. This widespread use of this class of antibiotics has displayed their safety profile, which is actually more favorable than many other drug classes. The cardiac toxicity issue at the center of this discussion is the prolongation of the QT interval leading to torsade de pointes. Ciprofloxacin and levofloxacin, two of the more commonly used fluoroquinolones, are considered less likely than other fluoroquinolones to prolong the QT interval. The authors set out to evaluate the effect on the QT interval of patients after administration of ciprofloxacin and levofloxacin. Methods:A prospective evaluation of 38 consecutive patients evaluated by the infectious disease service and receiving either ciprofloxacin or levofloxacin was undertaken. Twelve-lead electrocardiograms were obtained at baseline and at least 48 hours after the first dose of the antibiotic was administered. Both the longest QT interval and the mean QT interval were evaluated. To account for variations in heart rate, the corrected QT interval was calculated by using Bazett's formula (QTc = QT/√R-R). Statistical analysis was undertaken to assess for the presence of a change after the administration of the antibiotic. Results:Thirty-eight patients (mean age, 65 ± 19 years), 23 women and 15 men, were studied. There was a small but significant increase in the longest QTc intervals over baseline in patients receiving levofloxacin; there was no significant change in the mean QTc interval. However, one patient who received levofloxacin was, statistically, an outlier and, on retrospective analysis, had demonstrated severe electrolyte disturbances at the time of the study. When this patient was excluded, the increase in the longest QTc interval was not significant. Patients receiving ciprofloxacin did not demonstrate any significant change in the longest QTc interval or mean QTc interval. Conclusions:Neither levofloxacin nor ciprofloxacin significantly prolonged the mean QTc interval over baseline. When electrolyte deficiencies in one of the patients evaluated were taken into account, this also held true for the longest QTc interval. There is, therefore, evidence that taking ciprofloxacin or levofloxacin, assuming that there are not any concurrent risk factors, will not cause a significant prolongation in the QT interval.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. BMJ 2000;320:1158–1159.
2. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21:253S–272S.
3. Khan IA. Long QT syndrome: diagnosis and management. Am Heart J 2002;143:7–14.
4. Sedgewick ML, Lip G, Rae AP, et al. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159–166.
5. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs1994;47:51–65.
6. Ortho-McNeil Pharmaceutical. Levaquin (levofloxacin) package insert. Raritan, NJ; 2000.
7. Gilbert DN, Moellering RC Jr, Sande MA, Ed. Sanford Guide to Antimicrobial Therapy 2002. Thirty-second Ed. Jeb C. Sanford Publishers, Hyde Park, VT. 2002.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron1976;16:31–41.
9. Sorawicz B, Knoebel SB. Long QT: good, bad, or indifferent? J Am Coll Cardiol 1984;4:398–413.
10. Fuster V, Alexander RW, O'Rourke RA ed. Hurst's The Heart. 10th edition. 2001:McGraw-Hill, New York.
11. Moss AJ. Prolonged QT-interval syndromes. JAMA 1986;256:2985–2987.
12. Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385–398.
13. Chiang C, Roden DM. The long QT syndromes: Genetic basis and clinical implications. J Am Coll Cardiol 2000;36:1–12.
14. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000;45:557–559.
15. Frothingham R. Rates of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468–1472.
16. Rubenstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593–596.
17. Iannini PB, Tillotson GS. Evaluating the risk of cardiac toxicity. Pharmacotherapy 2001;21:261–262.
18. Katritsis D, Camm J. Quinolones: cardioprotective or cardiotoxic? PACE 2003;26:2317–2320.
19. FDC Report. FDA/PhRMA Task Force to assess QT risk by clinical markers. The Pink Sheet-Prescription Pharmaceutical and Biotechnology 1999;61:15–16.
20. Kahn JB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect; Correspondence. J Antimicrob Chemother 2000;46:847–848.
21. Al-Khatib A, Lapointe NM, Kramer JM, et al. A survey of health care practitioners' knowledge of the QT interval. J Gen Int Med 2005;20:392–396.
22. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval.JAMA 2003;289:2120–2127.
23. Owens Jr, RC Ambrose PG. Torsade de pointes associated with fluoroquinolones. Pharmacotherapy2002;22:663–668.
24. Bayer Corporation. Cipro (ciprofloxacin) package insert. West Haven, CT; 2000.
